Boston, MA 05\/22\/2014 (wallstreetpr) \u2013\u00a0<\/b>The largest biotechnology company by sales, Amgen, Inc. (NASDAQ:AMGN)<\/b>, is on the brink of bringing an allergic asthma treatment that could become a game-changer in the market and the company’s financial books.<\/p>\n
The company manufactures and markets a wide range of treatments and like cancer, asthma treatment is gaining prominence among the drugs Amgen is developing currently. In the latest drug development update, the company provided that its new experimental drug called AMG-157 showed compelling results in patients with allergic asthma symptoms in an early clinical test.<\/p>\n
Effective asthma treatment<\/b><\/p>\n
Asthma deaths are hitting alarming rates in the U.S. and around the world. The treatment for the condition will not only help support healthy life for millions of patients but also drive a significant amount of money in revenue for the drug developer.<\/p>\n
Researchers in the U.S. and Canada studying AMG-157 reported this week in The New England Journal of Medicine that AMG-157, which targets a protein that induces allergic asthmatic responses, showed compelling results in both early and late stage cases. The experimental treatment was tried on a small group of patients that had mild allergic asthma.<\/p>\n
In view of the encouraging early results, Amgen, Inc. (NASDAQ:AMGN) intends to enter Phase II study of AMG-157. Although the company would not reveal the timeline of the Phase II study, it has already started the recruitment of patients to enter the second phase of the study.<\/p>\n
According to the U.S. Centers for Disease Control and Prevention, millions of Americans suffer from asthma condition with deaths widespread in the U.S. In 2010 alone, more than 3,400 asthma deaths occurred and more than 400,000 patients were hospitalized in relation to asthma.<\/p>\n
A different treatment<\/b><\/p>\n
AGM-157 may be a different treatment in many ways for asthma patients. The experimental drug has not only already showed big promise in handling allergic asthma, but is also taken less frequently compared with the available asthma treatments that are usually taken on a daily basis. AGM-157 is taken once every four weeks.<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 05\/22\/2014 (wallstreetpr) \u2013\u00a0The largest biotechnology company by sales, Amgen, Inc. (NASDAQ:AMGN), is on the brink of bringing an allergic asthma treatment that could […]<\/p>\n","protected":false},"author":12,"featured_media":23206,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2831,1520],"stock_ticker":[],"class_list":["post-23202","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-amgen-inc-nasdaqamgn","tag-nasdaqamgn","entry"],"acf":[],"yoast_head":"\n